Undervurderte aksjer: Pfizer, Novo Nordisk, PDD Holdings

PARAGRAPH 1 --- On May 24, PDD Holdings, a Chinese e-commerce company, reported Q1 earnings, missing both revenue ($1.57B vs. $1.66B expected) and EPS ($0.03 vs. $0.09 expected) estimates. Despite the miss, the company is progressing in its business transformation, including the success of its Temu app in the U.S. Meanwhile, Pfizer and Novo Nordisk are trading at significant discounts relative to their future earnings, with shares of Pfizer at $37.86 and Novo Nordisk at $46.77, both well below analysts' average price targets of $55.33 and $60.73, respectively.

PARAGRAPH 2 --- The market impact was felt primarily in the e-commerce and healthcare sectors. PDD Holdings' miss triggered a 14% drop in its stock price, affecting investor sentiment towards Chinese e-commerce companies. Pfizer and Novo Nordisk, however, saw only minor price fluctuations, with investors likely focusing on their long-term growth potential. The undervalued status of these stocks could lead to increased buying activity, potentially driving up their share prices.

PARAGRAPH 3 --- Next, investors should watch for PDD Holdings' Q2 earnings release on August 23 to gauge the company's progress and potential recovery. Additionally, Pfizer's and Novo Nordisk's earnings releases on August 2 and August 3, respectively, will provide updates on their financial health and growth prospects. Lastly, the ongoing success of PDD Holdings' Temu app in the U.S. market will be a key catalyst to monitor, as it could drive a turnaround in the company's stock price.